Measles at the present stage

Aygerim Zhuzzhasarova, Dinagul Bayesheva, Alena Altynbekova, Bayan Turdalina, Aliya Seidullayeva, Aitolkyn Mynzhanova, Almagul Kushugulova

1 Astana Medical University, Nur-Sultan, Kazakhstan
2 Multidisciplinary City Hospital No 1, Nur-Sultan, Kazakhstan
3 Center of Life Sciences, Nazarbayev University, Nur-Sultan, Kazakhstan

Abstract
Measles is an acute infectious disease characterized by a combination of catarrhal symptoms and specific exanthema. This is a highly contagious, potentially fatal infection with an airborne transmission mechanism. A distinctive feature of the pathogen is the ability to cause prolonged post-infectious immunosuppression. Fever in combination with one of the following manifestations: cough, runny nose, conjunctivitis are the first clinical manifestations of the disease. The Belsky-Filatov-Koplik spots are specific rashes on the mucous membrane of the cheeks, allowing to establish a diagnosis even before the appearance of exanthema. The rash usually appears 3-4 days after the onset of an increase in body temperature and is characterized by a gradual rash, initially occurring on the face and behind the ears, which is associated with the peak of the clinical picture. Measles is characterized by a polysystemic lesion, with a predominant involvement in the pathological process of the central and respiratory systems of the body, while pneumonia is one of the most frequent complications that lead to a fatal outcome. In the treatment of measles, supportive therapy, correction of dehydration and nutrient deficiency, as well as treatment of secondary bacterial infections and providing the body with vitamin A are of great importance. It is important to note that measles has lifelong immunity after an infection or vaccination, while vaccination against measles plays a crucial role in its elimination. Previously, it was believed that measles is on the verge of eradication, but its outbreaks in Europe at the present stage have led to the return and spread of this infection. Measles remains the leading cause of global child mortality in the world, as children from developing countries are most susceptible to this disease. About 45 million new cases of measles are registered annually in the world, among which almost a million people die.

Key words: measles, children, clinic, diagnosis, treatment, prevention

Modern views of measles in children
Measles is a viral disease with a high potential for spread and the development of complications in about 30% of cases, the main contingent of patients are children under the age of 5 years, mainly with a nutritional deficiency and a weakened immune system. At the present stage, measles remains a significant morbidity and a significant cause of death worldwide, especially among young children, due to its widespread spread, even despite the availability of a safe and effective vaccine [1-7].

According to the World Health Organization, it was found that in 2013, about 145,700 people died from measles, most of them children, while about 95% of the deaths occurred in Africa and Asia [8-10]. The global measles burden exceeded 9.7 million cases in 2015. Of these, 254,928 cases were reported in six WHO regions, while 134,200 (95% CI=74,400-353,600) people died from this infection 16. 27,086 (88%) of these cases were reported in 4 countries: Kyrgyzstan-17,779 (58%), Bosnia and Herzegovina-4,583 (15%), Germany-2,383 (8%) and Kazakhstan-2,341 (8%) [11,12].

Measles is a potentially liquidable disease, since the reservoir is exclusively a person. Safe, effective vaccines, as well as sensitive and specific laboratory diagnostic tests, have been developed and are widely used today. The possibility of eliminating measles is due to the formation of lifelong immunity after an infection, the presence of a single antigenic variant of the measles virus worldwide, the absence of other than human reservoirs of the virus in nature, the pronounced manifestation of clinical forms of infection and the availability of effective live vaccines [13]. The World Health Organization (WHO) recommends a two-dose vaccination policy, with the first dose administered during the first year of life, and coverage
should be maintained at a level of at least 90-95% in order to interrupt the chain of transmission of the disease [14]. In 2015, measles outbreaks were registered in all 16 regions of the country in Kazakhstan. From January 1, 2015 to January 30, 2016, 2,679 suspected cases of measles were detected. The incidence of measles was recorded in people aged 20-29 years, 31% (n=719); adults aged 30 years and older, 26% (n=615); children under the age of one year, 25% (n=576); adolescents and young people aged 15-19 years, 13% (n=300). The registered incidence was the highest among people over 14 years of age, 70% (n=1634) [15].

The possibility of eradicating measles infection is due to the formation of lifelong immunity after infection, the presence of the only antigenic variant of the measles virus worldwide, the absence of other than human virus reservoirs in nature, the pronounced manifestation of clinical forms of infection and the availability of effective live vaccines [13]. The World Health Organization (WHO) recommends vaccination in two doses, with the first dose administered during the first year of a child's life, and vaccination coverage should be maintained at a level of at least 90-95% in order to interrupt the chain of transmission of the disease [14,15].

In Kazakhstan, measles outbreaks were registered in all 16 regions of the country in 2015. From January 1, 2015 to January 30, 2016, 2,679 suspected cases of measles were detected. The incidence of measles was recorded in people aged 20-29 years, 31% (n=719); adults aged 30 years and older, 26% (n=615); children under the age of one year, 25% (n=576); adolescents and young people aged 15-19 years, 13% (n=300). At the same time, the incidence was highest among people over 14 years of age, 70% (n=1634).

Thus, the fact remains relevant that measles is dangerous at the present stage. It should be noted that the most highly effective and affordable vaccines (live weakened measles vaccines) provide 97% protection at two doses administered at the age of 12 to 15 months and from 4 to 6 years, with proven safety indicators [16].

According to the latest WHO data, since 2000, measles vaccination has prevented about 21 million deaths worldwide. Despite this, the set global goals were not achieved and the risk of an increase in the incidence of measles by 31% of the number of cases registered worldwide between 2016 and 2017 remained. The World Health Organization (WHO) reported 117,075 cases of measles and 1,205 deaths in Madagascar observed between the beginning of October 2018 and the beginning of April 2019. In Europe, the number of registered cases in 2018 increased three times compared to 2017 and 15 times compared to 2016. In addition, endemic measles has been reported in several European countries where the elimination of this infection was previously achieved. In the WHO European Region, from January 1 to October 30, 2018, this figure was 53,201. Of these, 89% of all cases were registered in nine countries, such as: Ukraine-66% (n=35,120); Serbia-9.5% (n=5,057); France-5% (n=2,787); Italy (n=2,373; 4.5%); Greece (n=2,192; 4%); the Russian Federation (n=1,822; 3%); Georgia (n=1,502; 3%); Albania (n=1,405; 3%); Romania (n=943; 2%). The maximum increase in the incidence is in April and May, such an increase corresponds to the literature data characterizing the seasonality of measles [16,17].

Monitoring of the disease in the Republic of Kazakhstan indicates that the incidence of measles from November 2018 to December 30, 2019, amounted to 13,873 cases, of which 71.2% (n=9875) were children aged 6 months to 14 years.

As shown in Figure 1, the total number of cases of measles in the Republic of Kazakhstan in 2018 was 576 cases, of which 84% were children, 16% were adults. In 2019, the total number of cases of measles increased 23 times compared to 2018 and amounted to 13,297 cases. Changes in the age structure are noteworthy, so in 2019 the number of sick children decreased from 84% to -71%, but the incidence rates in adults increased from 16% to -29% (Figure 1). The incidence took on an outbreak character in 4 regions of the country, where the number of cases exceeded 1000 patients: Nur-Sultan - 22.9% (n=3181), in Shymkent - 22.3% (n=3095), in Mangystau - 10.3% (n=1428) and in Turkestan region - 8% (n=1110). Regions where the number of measles cases ranged from 200 to 1000: Atyrau (n=775), Almaty (n=617), Kyzylorda (n=535), Karaganda (n=364), Zhambyl (n=433), Akmol (n=312), Aktobe (n=283), North Kazakhstan (n=280), Pavlodar (n=208) regions and Almaty (n=850), up to 200 cases of the disease were registered in Kostanay (n=193), as well as in West Kazakhstan (n=122) and East Kazakhstan (n=87) regions.

Given the high contagiousness of the virus (98-99%), almost complete vaccination coverage of the population is required to prevent epidemic outbreaks (collective immunity up to 95%). However, every year there are increasing cases of refusal of vaccination, which are associated with misconceptions about the safety of the vaccine, especially those that have arisen as a result of repeatedly refuted claims about the link between the vaccine and autism. In addition, some people reject vaccination for religious reasons. A significant reason for medical withdrawal from vaccination may be severe immunosuppression [18].

Unlike many infectious diseases, measles is primarily a public health problem with a clear scientific solution. Every complication or death associated with measles was a preventable tragedy that could have been avoided with timely vaccination. The increase in the incidence of measles at the present stage in the countries of Europe and the CIS, including in our republic, observed in 2017-2019, is a big step back, so today there is a need for a detailed study of the features of the epidemic process of measles to assess the effectiveness of measures taken, substantiate new directions for improving the system of epidemiological surveillance, which will allow to justify a set of measures differentiated in accordance with the conditions of a certain area.

**Etiology and clinical manifestations of measles in children**

The causative agent of measles is a virus that belongs to the genus Morbillivirus, the family Paramyxoviridae [18,19] it has a spherical shape and a diameter of 100 to 200 nm [20-22]. Transmission of the infection occurs from a sick person, including with an atypical form of measles [23]. The virus is
transmitted by airborne droplets, which persists in the open air for up to 2 hours. The infection rate is 98-99% [24].

The genetic characteristics of the measles virus are determined by eight classes (A-H), which are divided into 24 genotypes. 20 group A viruses were distributed mainly in China, the United States, Russia and Argentina. The group of viruses B and C circulates most often in Japan, South Africa and the Philippines. Viruses of group D and E are registered mainly in Western Europe. Group F viruses are found in Africa. Group G viruses are circulating in Canada, Malaysia and Indonesia. Group H viruses were detected in China, Japan and Korea [24]. Genotypes of groups B, D and H were registered in Kazakhstan in the period 2010-2019. In the period from November 2018 to March 2019, there was a circulation of D8 and B3 strains (Figure 2), where the Dublin and Kabul genetic lines were established in the B3 genotype, which were characterized by high aggressiveness, pathogenicity and contagiousness.

Figure 2 - Diversity of wild-type measles virus genotypes in the Republic of Kazakhstan, 2010-2019

| Diversity of wild-type measles virus genotypes in the Republic of Kazakhstan, 2010-2019 |
|-----------------------------------------------|
| Genotype | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
| D4 | | | | | | | | | | |
| D8 | | | | | | | | | | |
| B3 | | | | | | | | | | |
| H1 | | | | | | | | | | |

Measles does not have gender selectivity, but literature data show that male children are mostly more likely to get sick [25]. Among the main causes of infection are contacts with sick people with fever and respiratory symptoms from areas endemic to measles, immunodeficiency conditions, insufficient nutrition and vitamin A deficiency, as well as the presence of an unfavorable premorbid background [26-33].

The incubation period of measles in general is from 7 to 21 days, on average it is 13-14 days from the moment of contact [34]. The prodromal period lasts from 2 to 4 days. Then comes the period of peak or catarrhal period of the disease, which is characterized by an increase in body temperature, a decrease in appetite, general weakness and the so-called triad of symptoms: runny nose, barking cough and conjunctivitis. Before the appearance of a rash on the mucous membrane of the cheeks, opposite the molars, an exanthema appears – these are the Belsky-Filatov-Koplik spots, which are a pathognomonic symptom of measles in the prodromal period. However, these spots are present only in 60-70% of patients and usually persist from 12 to 72 hours [35].

The appearance of an exanthema is possible in several ways: in the form of erythema, spots and papules that initially appear on the face, around the hairline, on the sides of the neck and behind the ears [27,36,37]. When spreading to the lower extremities, the rash merges in places [38,39-42]. (Fig. 3) More intensively rashes are located in the shoulder area [40,42]. The palms of the hands and the soles of the feet are almost always free of rash [21,42]. The rash period lasts from 5 to 10 days, then the rash disappears in the same order in which it appeared [41,43]. As the rash disappears, there is pigmentation with slight peeling [21,42]. At the same time, there is a constant cough that persists for several weeks. Patients may also experience pain in the throat, abdomen, cervical lymphadenopathy and, less often, splenomegaly [42].

Mild atypical forms of measles include abortive, mitiged and subclinical.

A mild course of measles is observed in people with already existing, but not fully formed immunity from measles, previous contact with the measles virus, transplacental transmission of antibodies against measles or receiving intravenous immunoglobulin [44]. Such patients have a longer incubation period, but lighter and less characteristic clinical manifestations, with a rapid regression of existing symptoms. It should be noted that patients with this form of infection are less contagious [43].

Atypical measles is registered among children vaccinated with the measles vaccine of the killed virus, who were subsequently exposed to the wild-type measles virus. In the period from 1963 to 1967, the vaccine with the killed measles virus was used in the United States, it increased the sensitivity of people to the antigens of the measles virus, but did not provide full protection. The complaints characteristic of atypical measles are headache and prolonged fever. The rash is usually maculopapular, but it can have a vesicular or petechial character, with a bluish tinge, starting on the distal parts of the extremities (including the palms of the hands and the soles of the feet) and spreading throughout the body. As a complication, severe pneumonia often develops, bilateral infiltrates and intra-thoracic lymphadenopathy are characteristic [42]. There may be swelling of the hands and feet, paraesthesia or hyperesthesia and hepatosplenomegaly [44]. Atypical measles is considered not contagious [45]. Complications after atypical measles occur in about 10-40% of patients, mainly in young children, the elderly, pregnant women, patients with malnutrition and immunodeficiency conditions [45].

A complication of measles

Every fifth patient who has had measles has a risk of complications, which are most often observed in children under the age of 5 years and adults over 20 years. The most common complications of measles occur as a result of immunosuppression and the layering of secondary bacterial flora.

Measles pneumonia is the cause of death in 60% of cases [20]. It can develop due to the action of the measles virus itself (Hecht's giant cell pneumonia), the layering of secondary viral (adenovirus, herpes simplex virus) or bacterial flora (Streptococcus pneumonia, staphylococcus aureus) [46]. Among the pathology from the ENT organs, complications may occur in the form of the development of otitis media, otosclerosis,
tonsillitis, sinusitis, laryngotracheobronchitis ("cinnamon
croup"), bronchitis [47,48]. Gastrointestinal complications
include gastroenteritis, gingivostomatitis, mesenteric
lymphadenitis, hepatitis, pancreatitis and appendicitis [49].
Among ophthalmic complications, keratoconjunctivitis is
observed, leading to blindness, especially in people with vitamin
A deficiency and corneal ulcers. Hematological complications
are most often thrombocytopenia and disseminated intravascular
coagulopathy. Cardiac complications manifest themselves in
the form of pericarditis and cardiitis [42]. Renal complications
lead to glomerulonephritis and acute renal failure [50]. Among
neurological complications, febrile convulsions, primary
measles encephalitis, acute postinfectious encephalomyelitis,
subacute sclerosing panencephalitis are observed [51].

The most severe complication of measles is measles
encephalitis. Primary measles encephalitis develops in about
one in 1000 measles patients, usually on the 5th day of the rash.
At the same time, about 10% of cases end fatally. Acute post-
infectious encephalomyelitis is an autoimmune demyelinating
disease that occurs in about one in 1000 measles patients and
manifests itself during the recovery period within 2 weeks after
the rash.

During pregnancy, measles is particularly dangerous
because of the increased risk of spontaneous abortion, premature
birth, as well as low fetal body weight at birth, intrauterine
death or stillbirth. Since a woman’s immunity decreases during
pregnancy, infection can lead to a fatal outcome [51].

Diagnosis and differential diagnosis
The most common confirmation of measles is carried out
by a laboratory method based on a positive serological study for
antibodies to immunoglobulin M (IgM) to measles with a four-
fold or more increase in the titer of specific IgG in dynamics,
isoantigen of the virus from cultures of mononuclear cells of blood,
urine, smears from the conjunctiva or nasopharynx and detection
of measles virus RNA using reverse transcriptase polymerase
chain reaction (RT-PCR) in blood samples, a smear from the
pharynx and nasopharynx or urine [51]. Unfortunately, measles-
specific IgM antibodies can be detected only 4 or more days
after the rash appears, which can lead to false negative results
if the examination is carried out earlier. Approximately 75% of
patients with measles-specific IgM antibodies are detected
within the first 72 hours after the rash appears, but almost all
affected children will have measles-specific IgM detected 96
hours after the rash appears. In addition, false positive results
can sometimes occur in patients with infectious mononucleosis,
rubella, parvovirus infection B19 and rheumatological diseases.
Testing of measles virus RNA using RT-PCR is more specific and
gives a positive result before the characteristic IgM antibodies to
measles appear, and allows identifying the genotype [52].

Observation
The clinical picture of measles, depending on the seasonality
and geographical location, can simulate the manifestations of
other viral diseases. It should be emphasized that MeV infection
in people with weakened immunity may not cause the typical
symptoms of measles, while often causing severe outcomes of
the disease, with the development of pneumonia [53]. Virological
surveillance data show a decrease in the overall genetic diversity
of measles, since the number of genotypes in the examined
patients decreased [54]. Sequencing of larger fragments of the
MeV genome makes it possible to increase the resolution of MeV
transmission routes, including the difference between several

Treatment
In our country, the treatment of children with measles is
carried out in accordance with the Clinical Protocol "Diagnosis
and treatment of measles in children" of the Republic of
Kazakhstan №. 4 of June 9, 2016. The basis is symptomatic
therapy, which includes the use of antipyretics, vitamins,
preventive measures, proper and enhanced nutrition [44]. In
the case of the addition of secondary bacterial flora, treatment
is carried out with appropriate antibiotics [44]. According
to the 2017 Cochrane Systematic Review, in the treatment of
patients with measles, vitamin A should be added orally once
a day for 2 consecutive days in age-related doses (50,000 IU,
100,000 IU and 200,000 IU for infants <6 months, infants aged
6 to 11 months and children older than 12 months, respectively),
which is associated with a significant reduction in mortality and
morbidity in children [49].

It should be noted that there is no specific antiviral therapy
for measles patients. Although in vitro studies have shown that
the measles virus is sensitive to ribavirin [36,59], however, its
clinical efficacy and safety profile were not evaluated in any
randomized controlled trial.

Prevention. Active immunization
Today, measles remains one of the causes of morbidity
and mortality of children worldwide, especially in developing
countries [60]. Universal immunization of children and
vaccination of all susceptible patients, including children
aged 6-11 months who are at a higher risk of contracting
measles: travelers to endemic areas, high school and college
students, medical personnel and those who are in the regions
of the measles outbreak with the measles vaccine [27,43] are
recommended. The only measles vaccine currently in use
contains live attenuated measles strains that multiply in the host
body, causing both humoral and cellular immunity [36, 40].
To eliminate measles, vaccination coverage of the population
should be more than 93% [36,40]. It should be noted that a dose
of measles vaccine administered at the age of 1 year or older
provides protection against measles from 93% to 95%, while
two doses administered at appropriate intervals are almost 100%
effective [22] a vaccine administered at the age of 9 months
provides protection only by 85% 54. Children who received one
dose of the measles vaccine before the age of 12 months should
receive two additional doses at intervals of at least 28 days after
12 months, since doses administered between 12 months should
not be considered valid [52].

The measles vaccine can be administered as a single
component (for example, in Russia and some African countries),
but more often they are administered in combination with mumps
and rubella (MMR) and the measles-mumps-rubella-chickenpox
vaccine. The vaccine against measles, mumps, rubella and
chickenpox has the same immunogenicity and safety profiles as
the CCP vaccine, except that the relative risk of febrile seizures
is doubled [52].
At the present stage, scientists in many countries are studying alternative methods of immunization to determine the possibility of overcoming the overwhelming effect of maternal antibodies, for the immunization of infants at an earlier age, especially in highly endemic regions [19]. Alternative routes are respiratory and intradermal vaccination using microneedles or disposable jet injectors without needles with cartridges, are also being considered in order to exclude the use of sharp objects that are currently injected subcutaneously [23,26].

The respiratory measles vaccine has been studied for the past 30 years, and in connection with this, the WHO Aerosol Medicines project was created to license a single respiratory method of delivering the measles vaccine. Understanding the average volume of an inhaled vaccine delivered deep into the lungs is important for determining the dose received during aerosolization. Studies show that an effective immune response occurs when the vaccine reaches the deep layers of the lungs, for this, the particles in aerosol form must have a size of <5 microns [27].

Reactions to the vaccine occur on average 5-12 days after vaccination, mainly manifested in the form of fever, rash and arthralgia [56]. Contraindications for vaccination are after vaccination, mainly manifested in the form of fever, rash and arthralgia [56]. Contraindications for vaccination are primarily hypersensitivity to any component of the vaccine, including gelatin and neomycin; a confirmed anaphylactic reaction to a previous measles vaccine in the anamnesis, cellular immunodeficiency, moderate or severe disease in the acute period, any febrile disease, pregnancy [61]. Measles vaccination should be postponed for those who have recently taken high doses of corticosteroids, immunoglobulins or blood products [58].

Conclusion
An increase in measles disease in the Republic of Kazakhstan for 2018-2019 has been registered. The majority of cases occur in children under 14 years of age 73% (n=10189). Measles at the present stage was accompanied with formidable complications, such as pneumonia, carditis, ARDS, etc. Thus, to eliminate measles among the population, universal immunization of children and vaccination of all susceptible people with an anti-measles vaccine is recommended. Immunization is the responsibility of society, the ultimate goal of which is the complete elimination and eradication of measles.

Disclosures: There is no conflict of interest for all authors.

Acknowledgements: None.

Funding: None.

References
1. Schoini P, Karampitsakos T, Avdikou M, Athanasopoulou A, Tsoukalas G, Tzouvelekis A. Measles pneumonitis. Adv Respir Med. 2019;87(1):63-67. doi: 10.5603/ARM.a2019.0010.
2. Imdad A, Mayo-Wilson E, Herzer K, Bhutta ZA. Vitamin A supplementation for preventing morbidity and mortality in children from six months to five years of age. Cochrane Database Syst Rev. 2017;3:CD000824. doi: 10.1002/14651858.CD000824.pub3.
3. Ilyas M, Afzal S, Ahmad J, Alghamdi S, Khurram M. The Resurgence of Measles Infection and its Associated Complications in Early Childhood at a Tertiary Care Hospital in Peshawar, Pakistan. Pol J Microbiol. 2020;69(2):1-8. doi: 10.33073/pjm-2020-020.
4. Duke T, Mgone CS. Measles: not just another viral exanthem. Lancet. 2003;361(9359):763-73. doi: 10.1016/S0140-6736(03)12661-X.
5. Moss WJ, Griffin DE. Measles. Lancet. 2012;379(9811):153-64. doi: 10.1016/S0140-6736(10)62352-5.
6. Robbins FC. Measles: clinical features. Pathogenesis, pathology and complications. Am J Dis Child. 1962; 103:266-73. doi: 10.1001/archpedi.1962.02080020278018.
7. Hall V, Banerjee E, Kenyon C, Strain A, Griffith J, Como-Sabetti K, Heath J, Bahta L, Martin K, McMahon M, Johnson D, Roddy M, Dunn D, Ehresmann K. Measles Outbreak - Minnesota April-May 2017. MMWR Morb Mortal Wkly Rep. 2017;66(27):713-717. doi: 10.15585/mmwr.mm6627a1.
8. Piccirilli G, Lazzarotto T, Chiaregini A, Serra L, Gabrielli L, Lanari M. Spotlight on measles in Italy: why outbreaks of a vaccine-preventable infection continue in the 21st century. Expert Rev Anti Infect Ther. 2015;13(3):355-62. doi: 10.1586/14787210.2015.1003808.
9. Sá Machado R, Perez Duque M, Almeida S, Cruz I, Sottomayor A, Almeida I, Oliveira J, Antunes D. Measles outbreak in a tertiary level hospital, Porto, Portugal, 2018: challenges in the post-elimination era. Euro Surveill. 2018;23(20):18-00224. doi: 10.2807/1560-7917.ES.2018.23.20.18-00224.
10. WHO warns that progress towards eliminating measles has stalled [http:// www.who.int/mediacentre/news/releases/2014/eliminating measles/en/]. Accessed 5 April 2017.
11. Patel M.K., Gacic-Dobo M., Strebel P.M., Dabbagh A., Mulders M.N., Okwo-Bele J., Dumolard L., Rota P.A., Kretsinger K., Goodson J.L. Progress toward regional measles elimination—Worldwide, 2000–2015. Morb. Mortal. Wkly. Rep. 2016;65:1228–1233. doi: 10.15585/mmwr.mm6533a2.
12. World Health Organization Regional Office for Europe. EpiBrief. 2016;1:1-11. Available at.
13. Seither R, Calhoun K, Knighton CL, Mellerson J, Meador S, Tippins A, Greby SM, Dietz V. Vaccination Coverage Among Children in Kindergarten - United States, 2014-15 School Year. MMWR Morb Mortal Wkly Rep. 2015;64(33):897-904. doi: 10.15585/mmwr.mm6433a2.
14. Orenstein WA, Hinman A, Nkowane B, Olive JM, Reingold A. Measles and Rubella Global Strategic Plan 2012-2020 midterm review. Vaccine. 2018;36 Suppl 1: A1-A34. doi: 10.1016/j.vaccine.2017.09.026.
15. Abeev A, Zhylkibayev A, Kamalova D, Kusheva N, Rusupbaeva G, Tleumbetova N, Beissnova S, Aubakirova S, Sassenova Z, Demessina B, Amambayev A, Ramankulov Y, Shetsov A. Epidemiological Outbreaks of Measles Virus in Kazakhstan during 2015. Jpn J Infect Dis. 2018;71(5):354-359. doi: 10.7883/yoken.JJID.2017.565.
16. Dabbagh A, Laws RL, Steulet C, Dumolard L, Mulders MN, Kretsinger K, Alexander JP, Rota PA, Goodson JL. Progress Toward Regional Measles Elimination - Worldwide, 2000-2017. MMWR Morb Mortal Wkly Rep. 2018;67(47):1323-1329. doi: 10.15585/mmwr.mm6747a6.

Journal of Clinical Medicine of Kazakhstan: 2021 Volume 18, Issue 6
56. Update of the nomenclature for describing the genetic characteristics of wild-type measles viruses: New genotypes and reference strains. Wkly. Epidemiol. Rec. 2003; 78:229–232.

57. Kessler, J.R.; Kremer, J.R.; Shulga, S.V.; Tikhonova, N.T.; Santibanez, S.; Mankertz, A.; Semeiko, G.V.; Samoilovich, E.O.; Tamfum, J.-J.M.; Pukuta, E.; et al. Revealing new measles virus transmission routes by use of sequence analysis of phosphoprotein and hemagglutinin genes. J. Clin. Microbiol. 2011; 49:677–683. doi: 10.1128/JCM.01703-10.

58. Gardy, J.L.; Naus, M.; Amlani, A.; Chung, W.; Kim, H.; Tan, M.; Severini, A.; Krajden, M.; Puddicombe, D.; Sahni, V.; et al. Whole-genome sequencing of measles virus genotypes H1 and D8 during outbreaks of infection following the 2010 Olympic winter games reveals viral transmission routes. J. Infect. Dis. 2015; 212:1574–1578. doi: 10.1093/infdis/jiv271.

59. Bichon A, Aubry C, Benarous L, Drouet H, Zandotti C, Parola P, Lagier JC. Case report: Ribavirin and vitamin A in a severe case of measles. Medicine (Baltimore). 2017;96(50):e9154. doi: 10.1097/MD.0000000000009154.

60. Paules CI, Marston HD, Fauci AS. Measles in 2019 - Going Backward. N Engl J Med. 2019;380(23):2185-2187. doi: 10.1056/NEJMp1905099.

61. Rota PA, Bankamp B. Whole-Genome Sequencing During Measles Outbreaks. J Infect Dis. 2015;212(10):1529-30. doi: 10.1093/infdis/jiv272.